 |
 |
thanks Linda for clarification, I'll be watching this too -------------------------------------------------- From: "[log in to unmask]" <[log in to unmask]> Sent: Friday, June 25, 2010 6:33 PM To: <[log in to unmask]> Subject: Re: Neurologix announces phase 2 trial is a success > hi Ray, > The phase II trial involved sterotactic brain surgery, and used a "gene > transfer product, a disabled virus with a gene called GAD, will be infused > into the STN bilaterally using stereotactic surgical techniques. The > overall goal of this approach is to normalize the activity of the STN and > reduce the motor symptoms of PD." > (http://clinicaltrials.gov/ct2/show/NCT00643890?term=gad&cond=parkinsons&rank=1 > It also stated that fior the phase II trial, previous brain surgery was > an exclusion, > we will have to wait awhile to learn what the trial III protocol will be > like. > > linda > > > > www.pdpipeline.org > > ---------- Original Message ---------- > From: Rayilyn Brown <[log in to unmask]> > To: [log in to unmask] > Subject: Re: Neurologix announces phase 2 trial is a success > Date: Thu, 24 Jun 2010 10:42:52 -0700 > > do you know what brain surgery is involved? I've had DBS does that > disqualify me? > > -------------------------------------------------- > From: "[log in to unmask]" <[log in to unmask]> > Sent: Wednesday, June 23, 2010 8:14 PM > To: <[log in to unmask]> > Subject: Fw: Neurologix announces phase 2 trial is a success > >> Neurologix Announces Successful Phase 2 Trial of Gene Therapy for >> Parkinson's Disease >> >> FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC >> Bulletin Board:NRGX.ob - News), today announced positive results in a >> Phase 2 trial of its investigational gene therapy for advanced >> Parkinson's >> disease (PD), NLX-P101. Study participants who received NLX-P101 >> experienced statistically significant and clinically meaningful >> improvements in off-medication motor scores compared to control subjects >> who received sham surgery. In the trial, this benefit was seen at one >> month and continued virtually unchanged throughout the six month blinded >> study period. The results also demonstrated a positive safety profile for >> NLX-P101, with no serious adverse events related to the gene therapy or >> surgical procedure reported. Patients enrolled in the trial had moderate >> to advanced PD and were not adequately responsive to current therapies. >> http://finance.yahoo.com/news/Neurologix-Announces-prnews-2701823243.html?x=0&.v=1 >> >> ---------------------------------------------------------------------- >> To sign-off Parkinsn send a message to: >> mailto:[log in to unmask] >> In the body of the message put: signoff parkinsn > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn